<div id="readability-page-1"><p>Rhumbline Advisers raised its holdings in  GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 42.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 27,610 shares of the company's stock after acquiring an additional 8,258 shares during the period. Rhumbline Advisers owned approximately 0.10% of GeneDx worth $2,549,000 at the end of the most recent quarter.</p><ul><li>Biotech Catalyst Alert: NKTR, CDTX &amp; WGS Rallying With Big Gains</li></ul><p>A number of other institutional investors have also bought and sold shares of WGS. US Bancorp DE boosted its holdings in shares of  GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company's stock worth $50,000 after purchasing an additional 548 shares during the last quarter.  AlphaQuest LLC lifted its position in  GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company's stock worth $70,000 after buying an additional 594 shares in the last quarter.  PNC Financial Services Group Inc. acquired a new position in  GeneDx during the first quarter worth $132,000.  Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in  GeneDx by 184.8% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,224 shares of the company's stock valued at $197,000 after buying an additional 1,443 shares in the last quarter.  Finally, Campbell &amp; CO Investment Adviser LLC purchased a new stake in  GeneDx in the 2nd quarter valued at $204,000. 61.72% of the stock is owned by hedge funds and other institutional investors. </p><h2>Insider Buying and Selling</h2><p>In other news, CFO Kevin Feeley sold 3,728 shares of the firm's stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $452,840.16. Following the completion of the transaction, the chief financial officer directly owned 8,755 shares in the company, valued at $1,063,469.85. This trade represents a 29.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Katherine Stueland sold 10,501 shares of the business's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total value of $1,275,556.47. Following the completion of the sale, the chief executive officer owned 14,578 shares in the company, valued at $1,770,789.66. This represents a 41.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 54,775 shares of company stock valued at $8,170,087. Company insiders own  29.60% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play</li></ul><p>Several research analysts have recently commented on the company. Zacks Research lowered GeneDx from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, October 2nd. Wall Street Zen cut shares of GeneDx from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 1st. Guggenheim  reiterated a &#34;buy&#34; rating and issued a $170.00 target price (up from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Canaccord Genuity Group  set a $160.00 price target on shares of GeneDx and gave the company a &#34;buy&#34; rating in a research note on Wednesday, October 29th. Finally, Piper Sandler raised their price target on shares of GeneDx from $120.00 to $140.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, September 11th. Seven investment analysts have rated the stock with a Buy rating, three have issued  a Hold rating and one  has assigned  a Sell rating to the company. According to data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $129.22.</p><p><b>Read Our Latest Report on GeneDx</b></p><h2>GeneDx Stock Down 1.8%</h2><p>Shares of WGS opened at $158.96 on Monday. The company's 50-day moving average price is $134.95 and its 200 day moving average price is $111.08. GeneDx Holdings Corp. has a 12-month low of $55.17 and a 12-month high of $170.87. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. The firm has a market cap of $4.60 billion, a P/E ratio of 1,766.22 and a beta of 1.98. </p><p>GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.21. The company had revenue of $116.74 million during the quarter, compared to analyst estimates of $104.33 million. GeneDx had a net margin of 0.52% and a return on equity of 20.22%.  On average, sell-side analysts forecast that  GeneDx Holdings Corp. will post 0.97 earnings per share for the current year. </p><h2>GeneDx Profile</h2> (Free Report)<p>GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than GeneDx</li><li>Asset Allocation Strategies in Volatile Markets</li><li>Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast</li><li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li><li>Five Below and Dollar Tree Earnings Signal a Shopper Shift</li><li>What is a Secondary Public Offering? What Investors Need to Know</li><li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li></ul><p><strong>Want to see what other hedge funds are holding WGS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V0dT?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V0dT"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in GeneDx Right Now?</h2><p>Before you consider GeneDx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.</p><p>While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Rhumbline Advisers increased its stake in GeneDx Holdings Corp. by 42.7% in Q2, owning 27,610 shares worth $2,549,000. Insider sales included CFO Kevin Feeley and CEO Katherine Stueland. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and an average price target of $129.22. GeneDx stock opened at $158.96, with a market cap of $4.60 billion.</p>

GeneDx Holdings Corp. $WGS Shares Purchased by Rhumbline Advisers